Taysha Gene Therapies announces updates from TSHA-102 clinical program

Taysha Gene Therapies (TSHA) “announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company’s analysis of the natural history study data at the 2025 International Rett Syndrome Foundation Rett Syndrome Scientific Meeting, taking place in Boston from June 9-11, 2025.” “We are excited to present data supporting our TSHA-102 clinical program and its potential to improve function or enable achievement of developmental milestones that would significantly improve quality of life. Importantly, these findings have increased our conviction in the differentiated potential of TSHA-102 to address the high unmet needs for patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President and Head of Research & Development at Taysha. “We appreciate IRSF and their ongoing partnership, as well as the individuals with Rett syndrome, their caregivers and the clinicians who contributed to the important research that has increased our understanding of the disease progression and supported our alignment with the Food and Drug Administration on a potential path to registration.”